Internal Medicine, Hematology & Oncology · Orlando, FL
NPI
1447214911
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
2501 N Orange Ave, Suite 689
Orlando, FL, 32804
Phone (407) 265-6627
Groups this clinician bills Medicare through
Medicare paid, 2024
$108K
1,098 services
Medicare patients, 2024
418
Average age 74
Drug cost, 2024
$2.8M
1,097 prescriptions
Company payments, 2025
$368K
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tarek M Mekhail was code 99214 (office e&m - established), 494 times for 275 patients. In total Tarek M Mekhail billed 1,098 services in 17 codes, and Medicare paid $108K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-04-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 494 | 275 | $89.42 | $44K |
| 99215 Office E&M - Established | Office | 266 | 133 | $135.46 | $36K |
| 99213 Office E&M - Established | Office | 142 | 131 | $68.26 | $9,692 |
| 99205 Office E&M - New | Office | 80 | 80 | $161.15 | $13K |
| 99212 Office E&M - Established | Office | 42 | 39 | $42.17 | $1,771 |
| 96372 Injection Administration | Office | 17 | 17 | $10.97 | $186 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 16 | 16 | $0.97 | $15.47 |
| 99233 Hospital E&M - Subsequent | Facility | 11 | 11 | $92.57 | $1,018 |
By year: 2022 $94K for 951 services; 2023 $91K for 873 services; 2024 $108K for 1,098 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 71 | 62 | $2.86 | $203 |
Medicare prescription drug claims, 2024
In 2024, the drug Tarek M Mekhail prescribed most often to Medicare patients was Ondansetron Hcl, with 106 prescriptions and refills. In total Tarek M Mekhail wrote 1,097 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ondansetron Hcl Generic | 106 | 107 | 71 | $2,875 |
| Prochlorperazine Maleate Generic | 94 | 94 | 68 | $1,272 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 89 | 92 | 36 | $3,093 |
| Levothyroxine Sodium Generic | 55 | 121 | 17 | $369 |
| Oxycodone Hcl Generic | 44 | 44 | 17 | $822 |
| Prednisone Generic | 39 | 48 | 18 | $246 |
| Tagrisso Osimertinib Mesylate | 38 | 38 | Under 11 | $629K |
| Revlimid Lenalidomide | 36 | 36 | Under 11 | $544K |
| Eliquis Apixaban | 34 | 34 | Under 11 | $20K |
| Alprazolam Generic | 33 | 33 | 16 | $252 |
| Lenalidomide Generic | 31 | 31 | Under 11 | $442K |
| Gabapentin Generic | 27 | 33 | Under 11 | $185 |
| Lorazepam Generic | 25 | 31 | 17 | $89.82 |
| Morphine Sulfate Er Morphine Sulfate | 24 | 24 | Under 11 | $796 |
| Folic Acid Generic | 22 | 54 | 13 | $157 |
Brand drugs: 264 claims; generic drugs: 833 claims; opioid claims: 185.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tarek M Mekhail $368K ($368K in general payments such as food, travel and fees) from 22 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $139K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 62 | $139K |
| E.R. Squibb & Sons, L.L.C. BMY | 49 | $101K |
| Daiichi Sankyo Inc. 4568.T | 45 | $48K |
| Regeneron Healthcare Solutions, Inc. REGN | 25 | $31K |
| Amgen Inc. AMGN | 31 | $28K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $16K |
| Janssen Biotech, Inc. JNJ | 5 | $2,405 |
| Coherus Oncology, Inc. CHRS | 4 | $1,994 |
| Abbvie Inc. ABBV | 1 | $1,500 |
| Delcath Systems DCTH | 1 | $219 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.